Antimicrobial peptide coating of dental implants: Biocompatibility assessment of recombinant human beta defensin-2 for human cells

International Journal of Oral and Maxillofacial Implants

Volumn 28, Issue 4, 2013, Pages 982-988

  Warnke, Patrick H ^a,b,c   Voss, Eske ^b   Russo, Paul A J ^d   Stephens, Sebastien ^a,c   Kleine, Michael ^e   Terheyden, Hendrik ^f   Liu, Qin ^b,c  

^a GRIFFITH UNIVERSITY   (Australia)

^b UNIVERSITY OF KIEL   (Germany)

^c BOND UNIVERSITY   (Australia)

^d FLINDERS UNIVERSITY   (Australia)

^e Planton GmbH   (Germany)

^f Rotes Kreuz Krankenhaus Kassel   (Germany)

Author keywords

Antimicrobial peptides; Biocompatibility; Human beta defensins; Human mesenchymal stem cells; Human primary osteoblasts; Implant dentistry

Indexed keywords

ANTIINFECTIVE AGENT; BETA DEFENSIN; DEFB4A PROTEIN, HUMAN; RECOMBINANT PROTEIN;

CELL CULTURE; CELL PROLIFERATION; DRUG EFFECTS; HUMAN; KERATINOCYTE; MESENCHYMAL STROMA CELL; OSTEOBLAST; TOXICITY; ARTICLE; DRUG EFFECT;

ANTI-INFECTIVE AGENTS; BETA-DEFENSINS; CELL PROLIFERATION; CELLS, CULTURED; HUMANS; KERATINOCYTES; MESENCHYMAL STROMAL CELLS; OSTEOBLASTS; RECOMBINANT PROTEINS;

EID: 84899772570     PISSN: 08822786     EISSN: None     Source Type: Journal    
DOI: 10.11607/jomi.2594     Document Type: Article

References (25)

1. Schneider JJ, Unholzer A, Schaller M, Schäfer-Korting M, Korting HC. Human defensins. J Mol Med (Berl) 2005; 83: 587-595.
2. Schroder JM, Harder J. Human beta-defensin-2. Int J Biochem Cell Biol 1999; 31: 645-651.
3. Warnke PH, Springer IN, Russo PA, et al. Innate immunity in human bone. Bone 2006; 38: 400-408.
4. Lehrer RI. Primate defensins. Nat Rev Microbiol 2004; 2: 727-738.
5. Morgera F, Pacor S, Creatti L, Antcheva N, Vaccari L, Tossi A. Effects on antigen-presenting cells of short-term interaction with the human host defence peptide beta-defensin 2. Biochem J 2011; 436: 537-546.
6. Yang D, Chertov O, Bykovskaia SN, et al. Beta-defensins: Linking innate and adaptive immunity through dendritic and T cell CCR6. Science 1999; 286: 525-528.
7. Niyonsaba F, Ogawa H, Nagaoka I. Human beta-defensin-2 functions as a chemotactic agent for tumor necrosis factor-alpha-treated human neutrophils. Immunology 2004; 111: 273-281.
8. Niyonsaba F, Iwabuchi K, Matsuda H, Ogawa H, Nagaoka I. Epithelial cell-derived human beta-defensin-2 acts as a chemotaxin for mast cells through a pertussis toxin-sensitive and phospholipase C-dependent pathway. Int Immunol 2002; 14: 421-426.
9. Soruri A, Grigat J, Forssmann U, Riggert J, Zwirner J. Beta-defensins chemoattract macrophages and mast cells but not lymphocytes and dendritic cells: CCR6 is not involved. Eur J Immunol 2007; 37: 2474-2486.
10. Otte JM, Werner I, Brand S, et al. Human beta defensin 2 promotes intestinal wound healing in vitro. J Cell Biochem 2008; 104: 2286-2297.
11. Chertov O, Michiel DF, Xu L, et al. Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils. J Biol Chem 1996; 271: 2935-2940.
12. Bhat S, Milner S. Antimicrobial peptides in burns and wounds. Curr Protein Pept Sci 2007; 8: 506-520.
13. Pfeufer NY, Hofmann-Peiker K, Mühle M, Warnke PH, Weigel MC, Kleine M. Bioactive coating of titanium surfaces with recombinant human beta-defensin-2 (rHubetaD2) may prevent bacterial colonization in orthopaedic surgery. J Bone Joint Surg Am 2011; 93: 840-846.
14. Liechty KW, MacKenzie TC, Shaaban AF, et al. Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med 2000; 6: 1282-1286.
15. Almeida-Porada G, Porada CD, Tran N, Zanjani ED. Cotransplantation of human stromal cell progenitors into preimmune fetal sheep results in early appearance of human donor cells in circulation and boosts cell levels in bone marrow at later time points after transplantation. Blood 2000; 95: 3620-3627.
16. Maitra B, Szekely E, Gjini K, et al. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant 2004; 33: 597-604.
17. Rasmusson I, Ringdén O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003; 76: 1208-1213.
18. Le Blanc K, Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med 2007; 262: 509-525.
19. Bartmann C, Rohde E, Schallmoser K, et al. Two steps to functional mesenchymal stromal cells for clinical application. Transfusion 2007; 47: 1426-1435.
20. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317.
21. Varoga D, Pufe T, Harder J, et al. Human beta-defensin 3 mediates tissue remodeling processes in articular cartilage by increasing levels of metalloproteinases and reducing levels of their endogenous inhibitors. Arthritis Rheum 2005; 52: 1736-1745.
22. Sahly H, Schubert S, Harder J, et al. Activity of human beta-defensins 2 and 3 against ESBL-producing Klebsiella strains. J Antimicrob Chemother 2006; 57: 562-565.
23. Baroni A, Schubert S, Harder J, et al. Antimicrobial human beta-defensin-2 stimulates migration, proliferation and tube formation of human umbilical vein endothelial cells. Peptides 2009; 30: 267-272.
24. Vilquin JT, Rosset P. Mesenchymal stem cells in bone and cartilage repair: Current status. Regen Med 2006; 1: 589-604.
25. Yin L, Dale BA. Activation of protective responses in oral epithelial cells by Fusobacterium nucleatum and human beta-defensin-2. J Med Microbiol 2007; 56(pt 7): 976-987.